Computer-Assisted Design of Peptide-Based Radiotracers

In medical imaging, techniques such as magnetic resonance imaging, contrast-enhanced computerized tomography, positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are extensively available and routinely used for disease diagnosis. PET probes with peptide-based targeting are typically composed of small peptides especially developed to have high affinity and specificity for a range of cellular and tissue targets. These probes’ key benefits include being less expensive than traditional antibody-based PET tracers and having an effective chemical modification process that allows them to be radiolabeled with almost any radionuclide, making them highly appealing for clinical usage. Currently, as with every pharmaceutical design, the use of in silico strategies is steadily growing in this field, even though it is not part of the standard toolkit used during radiopharmaceutical design. This review describes the recent applications of computational design approaches in the design of novel peptide-based radiopharmaceuticals.

[1]  R. Mach,et al.  Computational Chemistry for the Identification of Lead Compounds for Radiotracer Development , 2023, Pharmaceuticals.

[2]  V. Abbate,et al.  Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling , 2023, RSC medicinal chemistry.

[3]  P. Blower,et al.  Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes , 2022, Dalton transactions.

[4]  S. Mahler,et al.  Evaluation of Phage Display Biopanning Strategies for the Selection of Anti-Cell Surface Receptor Antibodies , 2022, International journal of molecular sciences.

[5]  K. Kopka,et al.  Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. , 2022, Molecular pharmaceutics.

[6]  V. Abbate,et al.  Recent progress in the imaging of c‐Met aberrant cancers with positron emission tomography , 2022, Medicinal research reviews.

[7]  A. Rescifina,et al.  Artificial Intelligence Technologies for COVID-19 De Novo Drug Design , 2022, International journal of molecular sciences.

[8]  W. Gao,et al.  Why 90% of clinical drug development fails and how to improve it? , 2022, Acta pharmaceutica Sinica. B.

[9]  H. Stark,et al.  Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties , 2021, ACS chemical neuroscience.

[10]  S. Koh,et al.  Development of a Low-Molecular-Weight Aβ42 Detection System Using a Enzyme-Linked Peptide Assay , 2021, Biomolecules.

[11]  H. Shan,et al.  Preclinical Evaluation of [64Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma. , 2021, Molecular pharmaceutics.

[12]  José L. Medina-Franco,et al.  Grand Challenges of Computer-Aided Drug Design: The Road Ahead , 2021, Frontiers in Drug Discovery.

[13]  Chunxiao Jiang,et al.  Artificial Intelligence Technologies for COVID-19-Like Epidemics: Methods and Challenges , 2021, IEEE Network.

[14]  R. Atkinson,et al.  Dipeptide Inhibitors of the Prostate Specific Membrane Antigen (PSMA): A Comparison of Urea and Thiourea Derivatives. , 2021, Bioorganic & medicinal chemistry letters.

[15]  V. Abbate,et al.  NHS-Functionalized THP Derivative for Efficient Synthesis of Kit-Based Precursors for 68Ga Labeled PET Probes , 2021, Biomedicines.

[16]  Yasuyoshi Watanabe,et al.  Review: PET imaging with macro- and middle-sized molecular probes. , 2020, Nuclear medicine and biology.

[17]  Thomas Ebenhan,et al.  In silico modelling in the development of novel radiolabelled peptide probes. , 2020, Current medicinal chemistry.

[18]  V. Abbate,et al.  FABP4 inhibitors 3D-QSAR model and isosteric replacement of BMS309403 datasets , 2018, Data in Brief.

[19]  R. Mikołajczak,et al.  Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor , 2018, EJNMMI Research.

[20]  E. Jáuregui,et al.  Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview. , 2017, Current protein & peptide science.

[21]  P. Blower,et al.  68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling , 2017, The Journal of Nuclear Medicine.

[22]  M. Graham,et al.  68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis , 2017, Journal of Nuclear Medicine.

[23]  H. Cui,et al.  Targeting Tumors with Small Molecule Peptides. , 2016, Current cancer drug targets.

[24]  A. Mishra,et al.  Synthesis, in silico screening and preclinical evaluation studies of a hexapeptide analogue for its antimicrobial efficacy , 2015 .

[25]  D. Dhawan,et al.  Preclinical Evaluation of a Potential GSH Ester Based PET/SPECT Imaging Probe DT(GSHMe)2 to Detect Gamma Glutamyl Transferase Over Expressing Tumors , 2015, PloS one.

[26]  P. Blower.  A nuclear chocolate box: the periodic table of nuclear medicine. , 2015, Dalton transactions.

[27]  F. Sobott,et al.  Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method , 2015, MethodsX.

[28]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[29]  C. Gaeta,et al.  DNA Recognition with Polycyclic‐Aromatic‐Hydrocarbon‐Presenting Calixarene Conjugates , 2014 .

[30]  L. Di.  Strategic Approaches to Optimizing Peptide ADME Properties , 2014, The AAPS Journal.

[31]  Carolyn J. Anderson,et al.  64Cu-Labeled Somatostatin Analogues Conjugated with Cross-Bridged Phosphonate-Based Chelators via Strain-Promoted Click Chemistry for PET Imaging: In silico through in Vivo Studies , 2014, Journal of medicinal chemistry.

[32]  B. Meibohm,et al.  Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides , 2013, Clinical Pharmacokinetics.

[33]  M. Bardor,et al.  Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins , 2012, Biotechnology journal.

[34]  Ajay N. Jain,et al.  Surflex-Dock: Docking benchmarks and real-world application , 2012, Journal of Computer-Aided Molecular Design.

[35]  U. Schumacher,et al.  Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. , 2011, Journal of medicinal chemistry.

[36]  H. Elovaara,et al.  Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. , 2011, Blood.

[37]  P. Conti,et al.  Target-specific delivery of peptide-based probes for PET imaging. , 2010, Advanced drug delivery reviews.

[38]  Bert L. de Groot,et al.  Ligand docking and binding site analysis with PyMOL and Autodock/Vina , 2010, J. Comput. Aided Mol. Des..

[39]  Masanori Onda,et al.  Reducing the immunogenicity of protein therapeutics. , 2009, Current drug targets.

[40]  K. Dill,et al.  Development of an optimized activatable MMP-14 targeted SPECT imaging probe. , 2009, Bioorganic & medicinal chemistry.

[41]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[42]  Wadih Arap,et al.  Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.

[43]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[44]  P. Kollman,et al.  A second generation force field for the simulation of proteins , 1995 .

[45]  K. Brown,et al.  Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands. , 2009, Methods in molecular biology.